Bradley Foster & Sargent Inc. CT decreased its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 1.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 103,654 shares of the company’s stock after selling 1,039 shares during the period. Bradley Foster & Sargent Inc. CT’s holdings in IDEXX Laboratories were worth $58,242,000 as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of IDXX. Harbour Investments Inc. increased its position in shares of IDEXX Laboratories by 13.3% during the fourth quarter. Harbour Investments Inc. now owns 136 shares of the company’s stock valued at $92,000 after purchasing an additional 16 shares during the period. Rockland Trust Co. lifted its position in IDEXX Laboratories by 4.4% in the fourth quarter. Rockland Trust Co. now owns 425 shares of the company’s stock worth $288,000 after purchasing an additional 18 shares during the period. Prime Capital Investment Advisors LLC lifted its position in IDEXX Laboratories by 0.5% in the fourth quarter. Prime Capital Investment Advisors LLC now owns 3,923 shares of the company’s stock worth $2,654,000 after purchasing an additional 18 shares during the period. Pinnacle Associates Ltd. lifted its position in IDEXX Laboratories by 1.5% in the fourth quarter. Pinnacle Associates Ltd. now owns 1,227 shares of the company’s stock worth $830,000 after purchasing an additional 18 shares during the period. Finally, Triad Wealth Partners LLC boosted its stake in IDEXX Laboratories by 3.1% during the first quarter. Triad Wealth Partners LLC now owns 600 shares of the company’s stock worth $337,000 after buying an additional 18 shares in the last quarter. Institutional investors own 87.84% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages have issued reports on IDXX. Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Tuesday, July 14th. UBS Group reduced their price objective on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. Stifel Nicolaus lowered their target price on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research note on Tuesday, March 31st. Finally, Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.
IDEXX Laboratories Price Performance
Shares of IDXX stock opened at $544.32 on Friday. The stock’s fifty day simple moving average is $556.27 and its 200 day simple moving average is $595.41. IDEXX Laboratories, Inc. has a one year low of $518.55 and a one year high of $769.98. The firm has a market cap of $42.94 billion, a price-to-earnings ratio of 40.08, a P/E/G ratio of 2.98 and a beta of 1.55. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. On average, analysts expect that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.
About IDEXX Laboratories
IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.
IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.
Featured Articles
- Five stocks we like better than IDEXX Laboratories
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
